

# BC Cancer Protocol Summary for Treatment of Cutaneous T-cell Lymphoma (Mycosis Fungoides/Sézary Syndrome) with Alitretinoin

**Protocol Code**

*LYALIT*

**Tumour Group**

*Lymphoma*

**Contact Physician**

*Dr. Vincent Ho*

## ELIGIBILITY:

Cutaneous T-cell lymphoma including mycosis fungoides and Sézary syndrome:

- Not responsive to topical steroids or mechlorethamine, or
- Not responsive to phototherapy, or patients cannot access phototherapy.

## EXCLUSIONS:

- Pregnancy or breast feeding
- High risk factors for pancreatitis (prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease etc), hepatic insufficiency, vitamin A intake greater than or equal to 15,000 unit/day

## TESTS

- Baseline: cholesterol, triglyceride, TSH, ALT
- If clinically indicated: cholesterol, triglyceride, TSH, ALT, lipase
- For females of childbearing potential:
  - Baseline: two pregnancy tests (HCG quantitative blood) done minimum 3 weeks apart; second test within 11 days of initiating therapy
  - Every week for 4 weeks during cycle 1: pregnancy test (HCG quantitative blood)
  - Prior to each cycle: pregnancy test (HCG quantitative blood)
  - 5 weeks following end of treatment: pregnancy test (HCG quantitative blood)

## PREMEDICATIONS:

None

## TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
alitretinoin	30 mg once daily	PO

One cycle consists of 28 days. Treat until disease progression

## DOSE MODIFICATIONS:

Dose reduction if required: 10 mg once daily

## PRECAUTIONS:

1. **Pregnancy Prevention:** alitretinoin is a known teratogen.
  - a. Physicians should **only** prescribe alitretinoin to females of childbearing potential if **ALL** the conditions described in the **TOCTINO Pregnancy Prevention Program for women of childbearing potential** are met.
  - b. Physicians prescribing alitretinoin to female patients of childbearing potential **must** use the TOCTINO Pregnancy Prevention Program. This Program includes comprehensive information about the potential risks of alitretinoin, a checklist for criteria which **must** be met prior to prescribing, detailed information on birth control options, a patient acknowledgement form to be completed, and monthly pregnancy reminders for physicians to use at each patient visit during the treatment period.

## References

1. Kapser C, Herzinger T, Ruzicka T, et al. Treatment of cutaneous T-cell lymphoma with oral alitretinoin. J Eur Acad Dermatol Venereol 2015;29:783-8. <https://doi.org/10.1111/jdv.12684>
2. GlaxoSmithKline Inc. Alitretinoin (PrTOCTINO) product monograph. Health Canada. [https://pdf.hres.ca/dpd\\_pm/00051888.PDF](https://pdf.hres.ca/dpd_pm/00051888.PDF) Accessed Jun. 28, 2021.